Agile Therapeutics (AGRX) Prices 5.5M Common Stock Offering at $6.35/Share

January 22, 2016 9:22 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Agile Therapeutics, Inc. (Nasdaq: AGRX) announced the pricing of its underwritten public offering of 5,511,812 shares of its common stock at a public offering price of $6.35 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $35 million. In addition, Agile Therapeutics granted the underwriters a 30-day option to purchase up to 826,771 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering will be sold by Agile Therapeutics.

William Blair and RBC Capital Markets are acting as joint book-running managers for the offering. In addition, Janney Montgomery Scott, Cantor Fitzgerald & Co., and FBR are acting as co-managers.

The offering is expected to close on or about January 27, 2016, subject to customary closing conditions.

The shares of common stock described above are being offered by Agile Therapeutics pursuant to its shelf registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained, when available, from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606; Telephone: (800) 621-0687 or by email at [email protected] and RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; Tel: (877) 822-4089; email: [email protected].

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings

Related Entities

William Blair, Cantor Fitzgerald, RBC Capital, Janney Montgomery Scott, S3